Presence of central nervous system (CNS) involvement requiring active treatment
Leukemia with active central nervous system (CNS) involvement
Active central nervous system (CNS) involvement by leukemia
Known active central nervous system (CNS) involvement by lymphoma, including parenchymal and/or lymphomatous meningitis
Active, uncontrolled central nervous system (CNS) involvement by lymphoma
Patients with known active central nervous system (CNS) involvement by lymphoma, including leptomeningeal involvement
Known active central nervous system (CNS) involvement by lymphoma should be excluded from this clinical trial
Active central nervous system (CNS) involvement with leukemia
Active, uncontrolled central nervous system (CNS) leukemia involvement
Subject has known active central nervous system (CNS) involvement from AML
Active central nervous system (CNS) involvement by lymphoma, including untreated symptomatic epidural disease
Patients with active central nervous system (CNS) involvement with lymphoma are not eligible
Participant has known active central nervous system (CNS) involvement with AML.
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
Active central nervous system (CNS) involvement by malignancy
Active central nervous system (CNS) metastases and/or leptomeningeal involvement
Known active central nervous system (CNS) involvement
Known active central nervous system (CNS) involvement by MM
Subject has known active central nervous system (CNS) involvement with AML
Evidence of active central nervous system (CNS) involvement
known active central nervous system (CNS) involvement by malignancy.
Active central nervous system (CNS) or testicular involvement by leukemia
No active central nervous system (CNS) metastatic disease. NOTE: Subjects with CNS involvement must meet ALL of the following to be eligible:
History of or known active central nervous system (CNS) involvement with AML
Active central nervous system (CNS) involvement or leptomeningeal involvement
Patients with known active central nervous system (CNS) disease, including leptomeningeal involvement
Active, untreated central nervous system (CNS) involvement
Active central nervous system (CNS)-only involvement by malignancy (note: participants with secondary CNS involvement are allowed on study)
Patients with active central nervous system (CNS) involvement with lymphoma are not eligible
History of or active central nervous system (CNS) or peripheral nerve stimulation (PNS) involvement
Has known clinically active central nervous system (CNS) involvement
Active central nervous system (CNS) involvement within the previous 2 months
Active central nervous system (CNS) involvement of the underlying malignancy
Active central nervous system (CNS) neoplastic involvement
Known active central nervous system (CNS) involvement
Patient with active central nervous system (CNS) involvement
Patients with active central nervous system (CNS) involvement by malignant cells
History of or known active central nervous system (CNS) involvement or leptomeningeal involvement
Active central nervous system (CNS) involvement or leptomeningeal metastases involvement
Known active central nervous system (CNS) involvement with AML at study entry
Has known clinically active central nervous system (CNS) involvement OR history of resolved CNS involvement by multiple myeloma
Patients with history of central nervous system (CNS) involvement or active CNS involvement by malignancy
Active central nervous system (CNS) involvement by malignancy
Active Central Nervous System (CNS) involvement by malignancy
Has known clinically active central nervous system (CNS) involvement
Have active leukemic involvement of the central nervous system (CNS).
Active central nervous system (CNS) involvement of disease
Active AML involvement of the central nervous system (CNS) with disease refractory to intrathecal chemotherapy
AML patients with known, active leptomeningeal/central nervous system (CNS) involvement
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Active central nervous system (CNS) involvement with leukemia
Participant has known active central nervous system (CNS) involvement with AML.
Any past or current Central Nervous System (CNS) involvement, including leptomeningeal leukemia.
Patients with active central nervous system (CNS) involvement with lymphoma should be excluded from this clinical trial
Patient with active central nervous system (CNS) involvement with lymphoid malignancy
Active diagnosis of central nervous system (CNS) involvement with CLL
Active central nervous system (CNS) disease involvement
Clinically active central nervous system (CNS) cancer involvement. Imaging to exclude CNS involvement not required.
Known active cerebral/meningeal involvement with lymphoma; asymptomatic patients with previously treated and resolved central nervous system (CNS) lymphoma involvement are permitted
Had evidence of active central nervous system (CNS) involvement
Active central nervous system (CNS) lymphoma/leukemia - Patients with prior CNS involvement are eligible provided that it has been treated and is in remission
Active or symptomatic central nervous system (CNS) disease or epidural involvement
Active involvement of the Central Nervous System (CNS).
Active central nervous system (CNS) involvement of their malignancy.
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Active central nervous system (CNS) involvement by malignancy
No active extramedullary leukemia or known active central nervous system (CNS) involvement by malignancy; such disease treated into remission is permitted
Patient must not have active central nervous system (CNS) involvement
Active central nervous system (CNS) involvement by malignant cells
EXCLUSION CRITERIA FOR ENROLLMENT (PRE-TRANSPLANT): Active involvement of the central nervous system with malignancy (previous central nervous system [CNS] involvement is allowed if clearance of CNS disease has been documented prior to enrollment)
Active central nervous system (CNS) involvement by malignant cells
Active central nervous system (CNS) involvement by malignant cells
Active central nervous system (CNS) involvement by malignant cells
Clinical suspicion of active central nervous system (CNS) involvement by leukemia
